Claire Roberts

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease

Keith A. Johnson, R. Sperling, P. Aisen, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Eric Marsh, Dennis Dlugos, Venkatesh Nagaraddi, 2018, The Lancet.

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

Anup D. Patel, E. Wirrell, O. Devinsky, 2018, The New England journal of medicine.

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial

O. Devinsky, I. Miller, R. Nabbout, 2018, Epilepsia.

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study

O. Devinsky, J. Halford, E. Thiele, 2019, Epilepsia.

Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program

J. Kaplow, M. Kanekiyo, S. Krause, 2021, The Journal of Prevention of Alzheimer's Disease.

Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4) (S21.001)

S. Benbadis, E. Thiele, E. Marsh, 2017 .

Amyloid burden assessed by three amyloid PET tracers in the elenbecestat MissionAD Phase 3 program

J. Kaplow, M. Kanekiyo, S. Krause, 2020 .